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Summary
Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome 
inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38-targeted monoclonal antibody, 
in patients with refractory multiple myeloma.
Methods In this open-label, multicentre, phase 2 trial done in Canada, Spain, and the USA, patients (age ≥18 years) 
with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome 
inhibitors and immunomodulatory drugs), or were refractory to both proteasome inhibitors and immunomodulatory 
drugs, were randomly allocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in 
part 1 stage 1 of the study, to decide the dose for further assessment in part 2. Patients received 8 mg/kg every 
4 weeks, or 16 mg/kg per week for 8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks (cycles 3–6), and then 
every 4 weeks thereafter (cycle 7 and higher). The allocation schedule was computer-generated and randomisation, 
with permuted blocks, was done centrally with an interactive web response system. In part 1 stage 2 and part 2, 
patients received 16 mg/kg dosed as in part 1 stage 1. The primary endpoint was overall response rate (partial 
response [PR] + very good PR + complete response [CR] + stringent CR). All patients who received at least one dose of 
daratumumab were included in the analysis. The trial is registered with ClinicalTrials.gov, number NCT01985126.
Findings The study is ongoing. In part 1 stage 1 of the study, 18 patients were randomly allocated to the 8 mg/kg 
group and 16 to the 16 mg/kg group. Findings are reported for the 106 patients who received daratumumab 
16 mg/kg in parts 1 and 2. Patients received a median of five previous lines of therapy (range 2–14). 85 (80%) 
patients had previously received autologous stem cell transplantation, 101 (95%) were refractory to the most recent 
proteasome inhibitors and immunomodulatory drugs used, and 103 (97%) were refractory to the last line of 
therapy. Overall responses were noted in 31 patients (29·2%, 95% CI 20·8–38·9)—three (2·8%, 0∙6–8∙0) had a 
stringent CR, ten (9·4%, 4∙6–16∙7) had a very good PR, and 18 (17·0%, 10∙4–25∙5) had a PR. The median time to 
first response was 1·0 month (range 0·9–5·6). Median duration of response was 7·4 months (95% CI 
5·5–not estimable) and progression-free survival was 3·7 months (95% CI 2·8–4·6). The 12-month overall survival 
was 64·8% (95% CI 51·2–75·5) and, at a subsequent cutoff, median overall survival was 17·5 months (95% CI 
13·7–not estimable). Daratumumab was well tolerated; fatigue (42 [40%] patients) and anaemia (35 [33%]) of any 
grade were the most common adverse events. No drug-related adverse events led to treatment discontinuation.
Interpretation Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients 
with multiple myeloma, with a favourable safety profile in this population of patients.
Funding Janssen Research & Development.
Introduction
Multiple myeloma is a malignant plasma cell disorder 
that is characterised by bone, renal, haematological, and 
infectious complications due to accumulation of clonal 
plasma cells in the bone marrow and pathogenic 
antibody production.1 Although survival has improved 
sub stantially with new drug classes (eg, proteasome 
inhibitors and immunomodulatory drugs), along with 
autologous stem cell transplantation, most patients will 
die from refractory disease.2,3 Outcomes for patients who 
are resistant to proteasome inhibitors (bortezomib 
and carfilzomib) and immunomodulatory drugs 
(lenalidomide, thalidomide, and pomalidomide) are 
especially poor. Before the availability of carfilzomib and 
pomalidomide, median expected overall survival in these 
patients was 9 months.4 Additional treatment can be 
complicated by cytopenias, secondary to poor 
haematological reserves, and comorbidities such as 
renal insufficiency. Therefore, effective treatments that 
target novel pathways with little toxicity and favourable 
tolerability are needed. Monoclonal antibodies are a 
novel class of agents in myeloma, targeting cell surface 
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markers, such as SLAMF7 (CS-1) and CD38, with few 
off-target effects.5
Daratumumab is a first-in-class, human IgG1 
monoclonal antibody that binds CD38-expressing 
malignant cells with high affinity and induces tumour cell 
death through diverse mechanisms of action, which 
include complement-dependent cytotoxicity,6,7 antibody-
dependent cell-mediated cytotoxicity,6,7 antibody-dependent 
cellular phagocytosis,7,8 and induction of apoptosis.7,9 In a 
first-in-human phase 1/2 study of daratumumab 
monotherapy (0∙005–24 mg/kg) in patients with relapsed 
or relapsed and refractory multiple myeloma, a maximum 
tolerated dose was not achieved.10 In an expansion cohort 
of this study, the overall response rate (ORR) was 36% with 
daratumumab 16 mg/kg.10
In the current phase 2 study, we assessed daratumumab 
in patients with multiple myeloma and an unmet medical 
need—specifically, those who were refractory to their most 
recent treatment regimen after receiving at least three 
previous lines of therapy (including proteasome inhibitors 
and immunomodulatory drugs), or whose disease was 
refractory to both the most recent proteasome inhibitors 
and immunomodulatory drugs they had received, 
irrespective of the number of previous lines of treatment.
Methods
Study design and participants
This two-part, open-label, multicentre, phase 2 study 
started on Sept 30, 2013, at 26 sites in Canada, Spain, 
and the USA, and is ongoing. Inclusion criteria for 
patients included age at least 18 years old, documented 
secretory multiple myeloma, and evidence of disease 
progression on or within 60 days of the last dose of the 
most recent previous treatment regimen, based on the 
International Myeloma Working Group criteria.11,12 
Eligible patients had responded to at least one previous 
treatment regimen, received an alkylating agent alone 
or in combination with other myeloma treatments, 
received at least three previous lines of treatment that 
included a proteasome inhibitor and an immuno-
modulatory drug, or had disease double refractory to the 
most recent proteasome inhibitor and immuno-
modulatory drug they had received, and had an Eastern 
Cooperative Oncology Group (ECOG) perform ance 
status score of 2 or lower.
Exclusion criteria included any antimyeloma treatment 
within 2 weeks, or autologous stem cell transplantation 
within 12 weeks, of day 1 of cycle 1, and meningeal 
involvement of multiple myeloma and other malig-
nancies within 5 years. Patients with absolute neutrophil 
counts of 1 × 10⁹ per L or lower, haemoglobin concentration 
of 75 g/L or lower, platelet counts of less than 50 × 10⁹ 
per L, and creatinine clearance of 20 mL/min per 
1∙73 mm² or lower were excluded. Other exclusion 
criteria were myocardial infarction within 1 year, 
uncontrolled or unstable angina, congestive heart failure 
(New York Heart Association Class III or IV), arrhythmia 
(grade 2 or higher), QTcF interval that was longer than 
470 ms, chronic obstructive pulmonary disease, persistent 
asthma, or a history of asthma within 5 years.
Ethics committees or institutional review boards at the 
study sites approved the study, which was done in 
Research in context
Evidence before this study
We searched PubMed on July 29, 2015, with no date restriction 
using the keywords “progression risk”, “overall survival”, 
“multiple myeloma”, “relapsed”, and “refractory”. From the 
45 articles identified, the evidence indicates that despite the 
introduction of new agents that have prolonged survival, 
multiple myeloma remains incurable because most patients 
relapse or become refractory to available treatments. 
Daratumumab, a human monoclonal antibody that binds 
CD38-expressing malignant cells, gained US Food and Drug 
Administration breakthrough therapy designation based on 
phase 1 data from a first-in-human study in patients with 
multiple myeloma who relapsed or were refractory to at least 
two previous therapies. The first-in-human study was expanded 
and we concurrently initiated our study to further investigate 
the selected dose schedule.
Added value of this study
The current study is the largest study so far of the 
single-agent activity of daratumumab 16 mg/kg in heavily 
pretreated patients with multiple myeloma who were 
refractory to both a proteasome inhibitor and an 
immunomodulatory drug. The overall response rate was 29% 
and responses were rapid, deep, and durable. Efficacy was 
consistent in subgroups based on previous therapy and 
patients’ characteristics, including age and renal function. 
Side-effects of daratumumab were clinically manageable, and 
no patient discontinued treatment because of drug-related 
adverse events. These data are in accord with results from the 
expansion of the first-in-human study in which the overall 
response rate was 36% in patients given daratumumab 
16 mg/kg monotherapy.
Implications of all the available evidence
As a result of this study, daratumumab was the first 
monoclonal antibody approved by the US Food and Drug 
Administration for the treatment of refractory myeloma. 
Daratumumab is indicated for patients who have received at 
least three previous lines of therapy, including a proteasome 
inhibitor and an immunomodulatory drug, or who are double 
refractory to a proteasome inhibitor and an 
immunomodulatory drug. Based on its efficacy, with rapid, 
deep, and durable responses, and its favourable safety profile, 
further activity in combination regimens is being investigated.
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accordance with the principles of the Declaration of 
Helsinki, the International Conference on 
Harmonisation, and the guidelines for Good Clinical 
Practice. All patients provided written informed consent.
Randomisation and masking
In part 1 stage 1 of the trial, patients were randomly 
allocated in a 1:1 ratio to the daratumumab 8 mg/kg group 
or 16 mg/kg group (≤20 patients per group). Central 
randomisation was done with an interactive web response 
system, and patients were randomly allocated to treatment 
with a computer-generated randomisation schedule 
prepared under the supervision of the vendor. 
Randomisation was balanced by use of permuted blocks, 
and stratification factors included International Staging 
System staging (I, II, or III) and refractory status (ie, 
refractory to either a proteasome inhibitor or an 
immunomodulatory drug, refractory to both a proteasome 
inhibitor and immunomodulatory drug, or not refractory 
to either). Refractory was defined as disease progression 
on or within 60 days of the last dose. No one was masked 
to treatment assignment.
Procedures
A dose of daratumumab could be discontinued if the 
dose was deemed to be ineffective (ie, did not meet 
specified criteria for continuation) or poorly tolerated, or 
both, based on the results from the first interim analysis, 
which was done about 8 weeks after the last patient was 
enrolled in part 1 stage 1 of the study. After the first 
interim analysis, patients treated with an ineffective or 
poorly tolerated dose could crossover to the more 
effective dose if it was in their best interest according to 
the investigator treating them. A second interim analysis 
was done after another 25 patients were treated for at 
least 8 weeks in stage 2 of part 1. In part 2 of the study, an 
expansion cohort of 65 patients was treated at the selected 
dose to assess safety and efficacy. Dose reductions were 
not permitted. Patients were treated until disease 
progression or unacceptable toxicity, and long-term 
follow-up began after treatment discontinuation. The 
planned end of the study at 18 months after the last 
patient received the first dose of daratumumab had not 
been reached. The results of a prespecified efficacy 
analysis about 6 months after the last patient received his 
or her first dose of daratumumab are presented.
Patients received one of two regimens of daratumumab 
intravenously: daratumumab at 16 mg/kg per week for 
8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks 
(cycles 3–6), then every 4 weeks thereafter (cycle 7 and 
higher); or daratumumab 8 mg/kg every 4 weeks 
continuously. First infusions of daratumumab were 
1000 mL at 50 mL/h. If no infusion-related reactions 
occurred, the dose was increased in 50 mL/h increments 
to 200 mL/h. Second infusions were 500 mL at 50 mL/h 
and increased to 200 mL/h. Subsequent 500 mL 
infusions were at 100 mL/h and increased to 200 mL/h. 
Pre-infusion medications, 1 h (±0·25 h) before dosing, 
were methylprednisolone (100 mg intravenously for the 
first and second infusions and 60 mg thereafter), 
paracetamol (650–1000 mg), and diphenhydramine 
(25–50 mg) or equivalent antihistamine drug. Oral 
methylprednisolone (20 mg) or equivalent was 
administered on the 2 days after all daratumumab 
infusions.
Outcomes
The primary endpoint was overall response rate (ORR; 
partial response [PR] + very good PR + complete response 
[CR] + stringent CR). Secondary endpoints included 
duration of response, progression-free survival (PFS), 
overall survival, and clinical benefit rate (minimal 
response + ORR). Response was confirmed on two 
consecutive measure ments, and data were assessed by an 
independent review committee.
Safety assessments were the monitoring of adverse 
events, physical examinations, electrocardiogram 
moni toring, clinical laboratory measurements, vital sign 
Figure 1: Trial profile
*Three patients were crossed over to the daratumumab 16 mg/kg group after 
the first interim analysis, but were not included in the efficacy analysis of the 
16 mg/kg group. †Treatment with 8 mg/kg was discontinued because the 
overall response rate did not meet the prespecified criteria for continuation.
157 patients assessed for eligibility
33 excluded
31 did not meet screening 
criteria
1 for other reasons
1 withdrew consent
34 patients randomly allocated
18 to daratumumab 8 mg/kg*16 to daratumumab 16 mg/kg 
First interim analysis to assess response†
25 additional patients enrolled to 16 mg/kg
group based on results of first interim analysis
Second interim analysis to confirm response
65 additional patients enrolled to 16 mg/kg group 
106 included in final analysis of 16 mg/kg group
Part 1
Part 2
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measurements, and ECOG performance status. Severity 
of adverse events was assessed with the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (version 4.03).13
Statistical analysis
Briefly, about 100 patients would be treated during the 
study for the selected dose schedule. Response 
assessments were done by an independent review 
committee using the International Myeloma Working 
Group response criteria.11,12 ORRs were reported with 
two-sided 95% exact CI. Additionally, the number and 
percentage of patients in each response category were 
presented. Time-to-event endpoints, including duration 
of response, PFS, and overall survival, were analysed 
descriptively with the Kaplan-Meier method. All patients 
who received at least one dose of daratumumab were 
used for efficacy and safety analyses.
The study is registered with ClinicalTrials.gov, number 
NCT01985126.
Role of the funding source
The clinical investigators and funder were responsible 
for adherence to the study design and analysis plan. The 
investigators and their research teams gathered the data, 
and the funder compiled the data for summation and 
analysis and confirmed its accuracy. The funder 
coordinated the development of the manuscript and 
funded writing assistance. The authors had full access to 
the study data, participated in the development of the 
manuscript, and made the final decision to submit the 
manuscript for publication.
Results
124 patients received at least one dose of daratumumab 
(18 received 8 mg/kg, 106 received 16 mg/kg; figure 1). 
The clinical cutoff date for primary analysis was 
Jan 9, 2015, 7·7 months after the last patient had received 
the first dose. At the first interim analysis, the 
Daratumumab 
16 mg/kg (n=106)
Age (years)
Median (range) 63·5 (31·0–84·0)
18 to <65 58 (55%)
65 to <75 36 (34%)
≥75 12 (11%)
Men 52 (49%)
Ethnic origin
White 84 (79%)
Black or African American 15 (14%)
Asian 4 (4%)
Not reported, other, unknown 3 (3%)
Eastern Cooperative Oncology Group score
0 29 (27%)
1 69 (65%)
2 8 (8%)
International Staging System staging
I 26 (25%)
II 40 (38%)
III 40 (38%)
Cytogenetics profile*
t (4; 14) 9 (10%)
del17p 16 (17%)
del13q 30 (32%)
amp1q21 23 (24%)
Other 43 (45%)
Renal function (baseline creatinine clearance)
≥1·0 mL/s ( ≥60 mL/min) 60 (57%)
0·5 to <1·0 mL/s (30 to <60 mL/min) 42 (40%)
<0·5 mL/s (<30 mL/min) 4 (4%)
Extramedullary plasmacytomas
≥1 14 (13%)
(Table 1 continues in next column)
Daratumumab 
16 mg/kg (n=106)
(Continued from previous column)
Time since initial diagnosis (years; median, range) 4·8 (1·1–23·8)
Lines of previous therapy
>3 87 (82%)
Median (range) 5 (2–14)
Previous proteasome inhibitor 106 (100%)
Bortezomib 105 (99%)
Carfilzomib 53 (50%)
Previous immunomodulatory drug 106 (100%)
Lenalidomide 105 (99%)
Pomalidomide 67 (63%)
Thalidomide 47 (44%)
Previous steroids 106 (100%)
Dexamethasone 106 (100%)
Previous autologous stem cell transplantation 85 (80%)
Refractory to
Both proteasome inhibitor and 
immunomodulatory drug
101 (95%)
Last line of previous therapy 103 (97%)
Bortezomib 95 (90%)
Carfilzomib 51 (48%)
Lenalidomide 93 (88%)
Pomalidomide 67 (63%)
Thalidomide 29 (27%)
Alkylating agent 82 (77%)
Bortezomib + lenalidomide 87 (82%)
Bortezomib + lenalidomide + carfilzomib 42 (40%)
Bortezomib + lenalidomide + pomalidomide 57 (54%)
Bortezomib + lenalidomide + carfilzomib + 
pomalidomide
33 (31%)
Data are number (%), unless otherwise indicated. *Cytogenetic abnormalities 
were detected by fluorescence in-situ hybridisation or karyotyping, or both at 
baseline (n=95).
Table 1: Patients’ demographic and baseline disease characteristics
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daratumumab 8 mg/kg group did not meet the criteria 
for expansion because of an ORR of 11·1% (95% CI 
1·4–34·7). Baseline characteristics of this group are 
presented in the appendix. Concurrent pharmacokinetic 
analyses of the 8 mg/kg dose in the first-in-human study 
indicated that drug concentrations were probably less 
than the trough threshold for target saturation.10 The 
results of these analyses also suggested that, although 
24 mg/kg daratumumab would have been well tolerated, 
the gain in clinical benefit would have been small with 
this dose compared with 16 mg/kg. Three patients in the 
8 mg/kg group crossed over to the 16 mg/kg group, and 
were included in the 8 mg/kg group in all analyses. At the 
second interim analysis, after an additional 25 patients 
were treated in the 16 mg/kg group, the cumulative ORR 
justified expansion of the study into part 2 and an 
additional 65 patients were enrolled.
All 106 patients in the daratumumab 16 mg/kg group 
had been previously treated with proteasome inhibitors 
and immunomodulatory drugs (bortezomib 105 [99%], 
carfilzomib 53 [50%], lenalidomide 105 [99%], pomali-
domide 67 [63%], and thalidomide 47 [44%]; table 1). All 
patients had received dexamethasone previously, and 
87 (82%) patients had previously received more than three 
lines of therapy. Patients were highly refractory, with 
103 (97%) refractory to the last line of therapy before 
enrolment in the study and 101 (95%) refractory to the 
most recent proteasome inhibitors and immuno-
modulatory drugs (table 1). Refractoriness to specific 
agents included alkylating agents (82 [77%] patients), 
pomalidomide (67 [63%] patients), carfilzomib (51 [48%] 
patients), and bortezomib plus lenalidomide (double 
refractoriness, 87 [82%] patients; table 1). 70 (66%) patients 
were refractory to at least three of four drugs: bortezomib, 
lenalidomide, pomalidomide, and carfilzomib, and 
33 (31%) patients were refractory to all four agents. 
Median time since initial diagnosis was 4·8 years (range 
1·1–23·8), median number of lines of previous therapy 
was five (range 2–14), and 85 (80%) patients received 
previous autologous stem cell transplantation (table 1).
The median and mean numbers of treatment 
cycles given to patients were 4∙0 (range 1–16) and 
5∙3  (SD 3∙7), respectively, with 40 (38%) patients 
receiving six or more cycles of daratumumab 16 mg/kg. 
Median duration was 7·0 h (range 1·5–14·3) for the 
first infusion of daratumumab (n=106), 4·2 h (2·7–8·5) 
for the second infusion (n=103), and 3·4 h (1·1–6·7) for 
subsequent infusions (n=1105). 90 (85%) of 106 patients 
discontinued daratumumab 16 mg/kg: 82 (77%) 
because of progressive disease, five (5%) because of 
treatment-unrelated adverse events, and three (3%) as a 
result of consent withdrawal because of symptoms 
related to disease progression.
In the daratumumab 16 mg/kg group, overall response 
was noted in 31 of 106 patients (ORR 29·2%, 95% CI 
20·8–38·9) based on assessment by an independent 
review committee (figure 2; table 2). Three (3%) patients 
achieved stringent CR, ten (9%) achieved very good PR, 
and 18 (17%) patients had PR (table 2). The clinical 
benefit rate was 34·0% (95% CI 25·0–43·8; table 2). The 
median time to first response was 1·0 month (range 
See Online for appendix
Figure 2: Swim-lane plot of responders in the daratumumab 16 mg/kg group
Black ovals indicate first response and white ovals indicate best response. VGPR=very good partial response. 
sCR=stringent complete response. PR=partial response. *Disease progression.
PR
PR
sCRPR
PR
PR
PR
PR
sCRPR
PR
PR VGPR
VGPR
VGPR
sCRVGPR
PR VGPR
PR *
PR *
VGPR *
PR *
PR *
PR VGPR *
PR *
PR *
PR *
PR *
PR VGPR *
VGPR *
PR *
PR *
VGPR *
PR *
VGPR *PR
0 1 2 3 4 5 6 7 8 9 11 12 13 14 1510
Time from first dose (months)
Daratumumab 16 mg/kg 
group (n=106)
Stringent complete response 3 (2·8%, 0·6–8·0)
Complete response 0
Very good partial response 10 (9·4%, 4·6–16·7)
Partial response 18 (17·0%, 10·4–25·5)
Minimal response 5 (4·7%, 1·5–10·7)
Stable disease 46 (43·4%, 33·8–53·4)
Progressive disease 18 (17·0%, 10·4–25·5)
Not evaluable 6 (5·7%, 2·1–11·9)
Overall response rate* 31 (29·2%, 20·8–38·9)
Clinical benefit rate† 36 (34·0%, 25·0–43·8)
Very good partial response or better‡ 13 (12·3%, 6·7–20·1)
Data are number (%, 95% CI). *Defined as stringent complete response, complete 
response, very good partial response, plus partial response. †Defined as overall 
response rate plus minimal response. ‡Defined as stringent complete response, 
complete response, plus very good partial response.
Table 2: Overall best responses
Articles
6 www.thelancet.com   Published online January 6, 2016   http://dx.doi.org/10.1016/S0140-6736(15)01120-4
Figure 3: Overall response rate 
in patient subgroups in the 
daratumumab 16 mg/kg 
group
Exact 95% CIs are provided. 
ORR=overall response rate. 
ISS=International Staging 
System. IMWG=International 
Myeloma Working Group. 
NE=not estimable.
All patients
Age (years)
18 to <65
65 to <75
≥75
Sex
Male
Female
Ethnic origin
White
Other
ISS staging
I
II
III
Number of lines of therapy
≤3
>3
Refractory to
Proteasome inhibitor
Immunomodulatory drug
Proteasome inhibitor+immunomodulatory drug
Proteasome inhibitor+immunomodulatory drug+alkylating agents
Last line of previous therapy
Bortezomib
Carfilzomib
Lenalidomide
Pomalidomide
Thalidomide
Alkylating agents
Bortezomib+lenalidomide
Bortezomib+lenalidomide+carfilzomib
Bortezomib+lenalidomide+pomalidomide
Bortezomib+lenalidomide+carfilzomib+pomalidomide
Bortezomib+lenalidomide+carfilzomib+pomalidomide+thalidomide
Carfilzomib+pomalidomide
Type of myeloma
IgG
Non-IgG
Renal function (baseline creatinine clearance)
≥1·0 mL/s (≥60 mL/min)
0·5 to <1·0 mL/s (30 to <60 mL/min)
<0·5 mL/s (<30 mL/min)
Bone marrow % plasma cells (baseline)
≤30
30 to ≤60
>60
Cytogenetics risk stratification per IMWG
High
Standard
Other (low risk or not done)
Extramedullary plasmacytoma at baseline
Yes
No
 31/106
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 9/36
 4/12
 17/52
 14/54
 25/84
 6/22
 10/26
 12/40
 9/40
 5/19
 26/87
 30/104
 30/102
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 18/79
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 26/95
 15/51
 26/93
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 9/29
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 9/42
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 7/33
 2/12
 11/39
 16/49
 15/57
 20/60
 11/42
 0/4
 16/48
 6/21
 8/35
 4/20
 20/68
 7/18
 3/14
 28/92
n/N
0 25 50
ORR (%)
75 100
ORR
 29·2%
 31·0%
 25·0%
 33·3%
 32·7%
 25·9%
 29·8%
 27·3%
 38·5%
 30·0%
 22·5%
 26·3%
 29·9%
 28·8%
 29·4%
 29·7%
 22·8%
 27·2%
 27·4%
 29·4%
 28·0%
 28·4%
 31·0%
 22·0%
 26·4%
 21·4%
 26·3%
 21·2%
 16·7%
 28·2%
 32·7%
 26·3%
 33·3%
 26·2%
 0·0%
 33·3%
 28·6%
 22·9%
 20·0%
 29·4%
 38·9%
 21·4%
 30·4%
(95% CI)
 (20·8–38·9)
 (19·5–44·5)
 (12·1–42·2)
 (9·9–65·1)
 (20·3–47·1)
 (15·0–39·7)
 (20·3–40·7)
 (10·7–50·2)
 (20·2–59·4)
 (16·6–46·5)
 (10·8–38·5)
 (9·1–51·2)
 (20·5–40·6)
 (20·4–38·6)
 (20·8–39·3)
 (21·0–39·6)
 (14·1–33·6)
 (18·9–36·8)
 (18·7–37·5)
 (17·5–43·8)
 (19·1–38·2)
 (18·0–40·7)
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 (2·1–48·4)
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NE
 (20·4–48·4)
 (11·3–52·2)
 (10·4–40·1)
 (5·7–43·7)
 (19·0–41·7)
 (17·3–64·3)
 (4·7–50·8)
 (21·3–40·9)
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0·9–5·6), and responses improved in eight (25∙8%) of 
31 patients over time (figure 2). Responses were noted in 
prespecified subgroups irrespective of previous lines of 
therapy and refractory status (figure 3). Overall responses 
were noted in 30 of 101 patients (29·7%, 21·0–39·6) who 
were refractory to both proteasome inhibitors and 
immunomodulatory drugs (figure 3), and in 20 of 
70 patients (28·6%, 18·4–40·6) who were refractory to at 
least three of four agents (bortezomib, lenalidomide, 
carfilzomib, and pomalid omide). Of 12 patients who 
were refractory to five agents (bortezomib, lenalidomide, 
carfilzomib, pomalidomide, and thalido mide), 
two (16·7%, 2·1–48·4) achieved responses after 
daratumumab treatment. Overall responses occurred in 
the non-treatment-based subgroups: three of 14 patients 
(21·4%, 4·7–50·8) with extramedullary disease, four of 
20 patients (20%, 5·7–43·7) with baseline high-risk 
cytogenetics, 11 of 42 patients (26·2%, 13·9–42·0) 
with moderate renal impairment (0∙5–1∙0 mL/s 
[30–60 mL/min]), and four of 12 patients (33·3%, 
9·9–65·1) older than 75 years (figure 3).
The median follow-up of patients was 9·3 months 
(range 0·5–14·4), and median duration of response was 
7·4 months (95% CI 5·5–not estimable [NE]). Median 
PFS was 3·7 months (95% CI 2·8–4·6; figure 4A), and 
the median overall survival was not reached (13·7–NE; 
figure 4B). The 12-month overall survival was 64·8% 
(95% CI 51·2–75·5). Median overall survival was not 
reached in responders and was 13·7 months (95% CI, 
8·6–NE) in non-responders (appendix). 29 (94%) of 
31 responders treated with daratumumab 16 mg/kg were 
still alive, compared with 45 (60%) of 75 non-responders. 
A subsequent clinical cutoff for a safety update to meet 
regulatory requirements was June 30, 2015. With this 
update, the median overall survival was 17∙5 months 
(13∙7–NE).
Daratumumab was well tolerated, and no patients 
discontinued because of drug-related treatment-emergent 
adverse events, infusion-related reactions, or death. The 
safety profile in the 8 mg/kg group was similar to that in 
the 16 mg/kg group (appendix). In the 16 mg/kg group, 
the most common haematological treatment-emergent 
adverse events of any grade (≥20%) were anaemia 
(35 [33%] patients), thrombocytopenia (27 [25%]), and 
neutropenia (24 [23%]; table 3). Grade 3 or higher anaemia 
and thrombocytopenia occurred more frequently in non-
responders (24 [32%] and 18 [24%] of 75 patients, 
respectively) than in responders (one [3%] and two [6%] of 
31 patients, respectively). Grade 3 or higher neutropenia 
rates were similar in non-responders (nine [12%]) and 
responders (four [13%]). Few patients required additional 
supportive care: 40 (38%) of 106 received red blood cell 
transfusions, 14 (13%) had platelet transfusions, and eight 
(8%) needed granulocyte colony-stimulating factor. Blood 
transfusions were unaffected by previously reported 
daratumumab inter ference with blood typing assays.14 
Fatigue (42 [40%] of 106 patients) and nausea (31 [29%] 
patients) of any grade were the most prevalent non-
haematological treatment-emergent adverse events in the 
16 mg/kg daratumumab group (table 3). 32 (30%) patients 
had serious treatment-emergent adverse events, and 
24 (23%) had grade 3 or 4 serious treatment-emergent 
adverse events. Infusion-related reactions occurred in 
Figure 4: Progression-free survival (A) and overall survival (B) in the daratumumab 16 mg/kg group
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45 (42%) patients and were predominantly grade 1 or 2 
(grade 3 occurred in five [5%] patients; no grade 4 infusion-
related reactions were reported). 39 (37%) patients 
experienced infusion-related reactions during the first 
infusion and only six (6%) patients had more than 
one infusion-related reaction. The most common (≥5%) 
infusion-related reactions included nasal congestion 
(13 [12%]), throat irritation (seven [7%]), and cough, 
dyspnoea, chills, and vomiting (six [6%] each; appendix). 
No patient discontinued daratumumab because of an 
infusion-related reaction. No immunogenicity was 
reported.
Five (5%) patients discontinued treatment because of 
treatment-emergent adverse events (two with general 
physical health deterioration (ie, progressive disease), and 
one each with H1N1 influenza, hypercalcaemia, and 
spinal cord compression). 31 (29%) patients died after 
treatment with daratumumab 16 mg/kg: 29 (27%) because 
of progressive disease and two (2%) because of adverse 
events (cardiorespiratory failure secondary to H1N1 
influenza complications, and general health deterioration 
secondary to complications of aspiration pneumonia).
Discussion
Daratumumab monotherapy showed substantial 
clinical activity, with an ORR of 29%, and was well 
tolerated in patients with multiple myeloma who had 
been heavily treated; most patients were double 
refractory to bortezomib and lenalidomide, and many 
were refractory to pomalidomide or carfilzomib. 
Resistance to any previous therapy had no effect on the 
activity of daratumumab, lending support to a novel 
mechanism of action, but these findings need to be 
confirmed in larger studies. Similar response rates 
were also noted in patients with moderate renal 
impairment, older than 75 years of age, and with 
extramedullary disease or high-risk baseline cytogenetic 
characteristics.15 Although this study did not have a 
control arm, patients with the degree of treatment 
refractoriness in our study historically have poor 
outcomes.4 Follow-up is ongoing and thus more 
complete survival data will become available.
The results of our study corroborate the previously 
reported efficacy of daratumumab 16 mg/kg mono-
therapy in relapsed or refractory patients with multiple 
myeloma.10 Elotuzumab, a monoclonal antibody in 
development that targets SLAMF7,5 but lacks single-agent 
activity,16 increased median PFS by 4∙5 months compared 
with the control arm in combination with lenalidomide 
and dexamethasone in a population of patients who were 
less heavily pretreated than those in the our study.17
Deep responses of very good PR or better, particularly 
stringent CR, are associated with improved long-term 
outcomes in patients with newly diagnosed multiple 
myeloma.18,19 Whether the same trend occurs in patients 
with relapsed and refractory multiple myeloma remains 
to be seen, although many patients treated in our study 
had responses to daratumumab that improved over time 
and might contribute to prolonged overall survival. 
These high-quality responses (9% very good PR, 3% 
stringent CR) are notable in treatment-refractory 
patients with multiple myeloma. The rate of high-quality 
responses with single-agent daratumumab were higher 
than those with pomalidomide monotherapy in the mm-
002 clinical trial (2% of patients with at least a very good 
PR).20 61% of 108 patients in the pomalidomide 
monotherapy group were refractory to lenalidomide and 
bortezomib, and had received a median of five previous 
lines of therapy. In the PX-171-003-A1 study21 of 
carfilzomib monotherapy in 266 patients, responses of 
very good PR or better were noted in 6% of patients.
Similar to the present study and mm-002,20 the patients 
were heavily pretreated with a median of five lines of 
therapy and 64% were refractory to lenalidomide and 
bortezomib. Peri-infusion doses of corticosteroids were 
used in our study to manage infusion-related reactions, 
and were thought to be substantially lower than the 
therapeutic use of dexamethasone in earlier lines 
of therapies to treat multiple myeloma. Thus, 
daratumumab can be regarded as a monotherapy in 
these patients who were refractory to dexamethasone.
When considering daratumumab monotherapy for 
treatment of refractory multiple myeloma, it should be 
placed in the context of other combination regimens that 
are in use in these patients. In the pomalidomide alone 
versus pomalidomide plus low-dose dexamethasone 
treatment groups of the mm-002 phase 2 study, 61% and 
62% of 108 and 113 patients, respectively, were refractory 
to both bortezomib and lenalidomide, and in these 
double-refractory patients the ORR was 21% and 31%, 
median PFS was 2·0 and 3·8 months, median duration 
of response was 11·4 and 6·5 months, and median 
overall survival was 12·5 and 13·4 months, respectively.20 
In the PX-171-003-A1 study, in those treated with 
carfilzomib monotherapy who were refractory to both 
bortezomib and lenalidomide, the ORR was 15%, 
median duration of response was 7·8 months, and 
median overall survival was 11·9 months.21 Thus, the 
ORR of 29%, median PFS of 3·7 months, and median 
Daratumumab 16 mg/kg (n=106)
Any grade Grade 3 or 4
Fatigue 42 (40%) 3 (3%)
Anaemia 35 (33%) 25 (24%)
Nausea 31 (29%) 0
Thrombocytopenia 27 (25%) 20 (19%)
Neutropenia 24 (23%) 13 (12%)
Back pain 23 (22%) 3 (3%)
Cough 22 (21%) 0 (0%)
Data are number (%).
Table 3: Most common (≥20%) treatment-emergent adverse events
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duration of response of 7·4 months in our ongoing study 
of daratumumab monotherapy compare favourably with 
these agents, particularly because most of the patients 
were refractory to both proteasome inhibitors and 
immunomodulatory drugs (95%), and many were 
refractory to pomalidomide (63%) or carfilzomib (48%; 
table 1).
Daratumumab has a favourable safety profile 
compared with other available agents, and results in 
clinically manageable side-effects. No patient treated 
with 16 mg/kg discontinued daratumumab treatment 
because of a treatment-related adverse event. This result 
compares favourably with the substantial risk of 
neutropenia, febrile neutropenia, and infections with 
pomalidomide and dexamethasone reported in other 
studies. Additionally, non-haematological toxicities, 
such as cardiopulmonary and renal side-effects, are an 
important consideration with carfilzomib, particularly in 
patients with advanced disease.21,22 Lower rates 
of neutropenia were reported with single-agent 
daratumumab, and patients only routinely received 
steroids during the peri-infusion period and there was 
low use of granulocyte colony stimulating factor. 
Infusion-related reactions were easily managed, were 
usually grade 1 or 2, and did not lead to discontinuation. 
The overall favourable toxicity profile of daratumumab 
makes it an attractive drug for use in combination 
regimens, and it has shown early promising activity in 
combination with lenalidomide and dexamethasone.23
In conclusion, daratumumab seems to be an effective 
option for patients with relapsed and refractory multiple 
myeloma for whom available treatments have been 
exhausted. Based on deep and durable responses and a 
favourable safety profile, daratumumab 16 mg/kg seems 
suitable for treatment of patients with multiple 
myeloma. The tolerability of daratumumab in 
combination with other backbone agents is being 
assessed in early phase studies.24 Patients with early to 
late stages of multiple myeloma are being enrolled in 
randomised phase 3 studies of daratumumab in 
combination with bortezomib, or lenalidomide and 
dexamethasone, and other combinations, for the 
assessment of efficacy and safety, including patient-
reported outcomes.25
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